Chronic fetal hypoxia is a major challenge to fetal development, arising from placental insufficiency and underlying fetal growth restriction, which affects close to 10% of pregnancies worldwide. Understanding how the fetus adapts to oxygen deprivation is therefore fundamental to understanding survival before birth and cardiovascular health across the life course.
Our work overturned the prevailing view that the carotid body is inactive before birth, establishing its central role as the oxygen sensor initiating fetal cardiovascular defence to acute hypoxia. The carotid chemoreflex triggers peripheral vasoconstriction, redistributing blood flow towards vital organs – the fetal brain-sparing response. This vasoconstriction is sustained by hormones released into the fetal circulation and fine-tuned by our discovery of a local redox signalling pathway through interactions between nitric oxide and superoxide.
When fetal hypoxia becomes chronic, this defence is fundamentally reprogrammed. Carotid chemoreflex and sympathoadrenal responsiveness are attenuated, limiting the energetic cost of sustained neural activation, while control shifts towards local cardiovascular mechanisms. In the hypoxic fetus, peripheral vessels develop enhanced α-adrenergic responsiveness and a pro-constrictor redox phenotype, while cerebral vasodilator capacity and mechanisms supporting myocardial function are enhanced. These adaptations may help sustain redistribution of the fetal circulation during chronic hypoxia, but they come at a cost: the chronically hypoxic fetus has little additional cardiovascular reserve when acute hypoxia is superimposed. This provides a physiological explanation for the particular vulnerability of the growth-restricted fetus to acute stresses such as labour. Persistent hypoxia also transforms physiological redox signalling into oxidative stress. In the placenta, increased mitochondrial generation of reactive oxygen species quenches nitric oxide, reducing uteroplacental blood flow and fetal oxygen and nutrient delivery, thereby exacerbating fetal growth restriction.
Birth removes the chronic hypoxic stimulus, but the fetal cardiovascular legacy persists. We propose that the pro-constrictor phenotype that helped sustain fetal brain sparing becomes unmasked after birth as sympathetic vascular hyperreactivity and endothelial dysfunction, ultimately promoting hypertension in later life. Our latest work shows that maternal treatment of hypoxic pregnancy with the mitochondria-targeted antioxidant MitoQ protects placental function, restores perfusion, and prevents both fetal growth restriction and programmed hypertension in adult offspring. These findings establish mitochondria-derived oxidative stress as a causal mechanism linking chronic fetal hypoxia to cardiovascular disease in later life.
Thus, fetal hypoxia reveals a fundamental physiological continuum: from how the fetus senses and defends itself against oxygen deprivation, to how persistent fetal hypoxia transforms physiological adaptation into mechanisms that drive cardiovascular disease in later life.